JW Therapeutics (Shanghai) Co., Ltd.

DUBLIN--(BUSINESS WIRE)--The "CAR-T Funding Report - Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2025" has been added to ResearchAndMarkets.com's offering. In recent years, the CAR-T industry has experienced a remarkable surge in funding. CAR-T therapies have catalyzed a funding boom, with start-ups being richly supported by investors and large pharmaceutical companies eager to penetrate this burgeoning area of regenerative medicine. Globally, over 170 companies are actively developing CAR-T products, with 1,944 therapies in various development stages. Companies have engaged in approximately 110 collaboration agreements to advance their CAR-T candidates, with only 38 of these deals publicly disclosing a collective value of $23.58 billion. The estimated value for all collaborations could ascend to $67.9 billion. This industry garners significant interest from venture capitalists worldwide. Since 2014, 89 CAR-T companies have raised $7.7 billion in venture capital, paving the way for technological advancement and diversification into therapies for hematological and other cancers. Despite a slow IPO market in 2024, exemplified by Kyverna Therapeutics' $319 million raise, 42 companies have gone public since 2014, amassing $6.4 billion to enhance their platforms and strategies. Currently, the industry boasts 72,418 patent records, with 452 patents granted, highlighting that major pharmaceutical companies are eager to license these innovations. Over ten years, 91 CAR-T licensing deals have reached a valuation of $6.3 billion, a figure expected to rise dramatically over the next decade. The year 2023 witnessed a resurgence in dealmaking, although 2024 saw a dip in mergers and acquisitions (M&A) with merely two consummated deals. Significant M&A activity may not return in 2025. However, further deals are anticipated as pharmaceutical companies seek to invest their reserves. M&A deals have played a pivotal role in industry financing, generating a total of $97.4 billion. Across varying deal types-including IPOs, licensing, collaborations, and M&A transactions-the CAR-T sector has amassed over $141.2 billion. With many deals undisclosed, estimates suggest the industry financing might soar to $281.7 billion. Globally Approved CAR-T Therapies Since 2017, 13 CAR-T cell therapies have been commercialized across global healthcare markets. Seven therapies received U.S. FDA approval, with subsequent global endorsements. China's National Medical Products Administration has validated four therapies, while India's Central Drugs Standard Control Organisation approved two. The existing 13 therapies are exclusively for blood cancer treatment, serving less than 5% of global cancer patients. There are currently around 1,944 clinical trials aimed at blood and solid tumors, driven by an impressive 90% remission rate in approved therapies. CAR-T Market Overview The comprehensive 220-page CAR-T market funding report reviews global investment trends within the sector, detailing financing rounds, IPOs, M&A, strategic alliances, and profiling 78 leading competitors. Benefits of this Report: To summarize, CAR-T entities, from innovative start-ups to extensive enterprises, have engaged in numerous financial endeavors worth hundreds of billions. This report reveals critical insights into the financial dynamics shaping the industry, showcasing capital allocations and strategic opportunities for growth. Key Topics Covered: Companies Featured A2 Biotherapeutics Adicet Bio AffyImmune Therapeutics Allogene Therapeutics Arcellx Arsenal Biosciences Artiva Biotherapeutics Atara Biotherapeutics Autolus Therapeutics AvenCell Therapeutics Bellicum Pharmaceuticals BioNTech Biosceptre Cabaletta Bio Capstan Therapeutics Cargo Therapeutics Caribou Biosciences Carina Biotech CARsgen Therapeutics Cellares Cellular Biomedicine Group Celularity Celyad Oncology Clade Therapeutics Coeptis Therapeutics CRISPR Therapeutics Currus Biologics Dynamic Cell Therapies EXUMA Biotech Gracell Biotechnologies IASO Biotherapeutics ImmPACT Bio Immuneel Therapeutics Inceptor Bio Interius BioTherapeutics Juno Therapeutics Juventas Cell Therapy JW Therapeutics Kyverna Therapeutics Legend Biotech Leman Biotech Leucid Bio Limula March Biosciences Mnemo Therapeutics MPC Therapeutics Mustang Bio Noile-Immune Biotech OneChain Immunotherapeutics OriCell Therapeutics PeproMene Bio Poseida Therapeutics Precigen Precision BioSciences SOTIO Biotech Synthekine TC BioPharm Tessa Therapeutics Ucello Therapeutics Umoja Biopharma Verismo Therapeutics Vor Biopharma Wugen Xenetic Biosciences For more information about this report visit https://www.researchandmarkets.com/r/kmq25o About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Frazier Life Sciences, a decades-old biotech investor, is raising another heap of dry powder to create and invest in startups, according to publicly available documents from one of its investors. The Palo Alto, CA-based firm is patching together Frazier Life Sciences XII, according to meeting materials from the New Mexico State Investment Council, a limited partner. It would be a successor to Frazier’s $987 million FLS XI, which was disclosed in early 2022. The council has approved up to $50 million in commitments to FLS XII, according to the document from February. The Fairfax County Police Officers Retirement System, another Frazier investor, also had a motion for FLS XII in a recent meeting agenda . It isn’t clear how much money Frazier is targeting for FLS XII. For the last fund, Frazier was able to secure more than 20% above its original target. A spokesperson for the firm declined to comment. Frazier has been beefing up its team in recent months, bringing in new venture partners like former Alpine Immune Sciences executives Mitchell Gold and Stanford Peng, and former JW Therapeutics CEO James Li. According to its presentation to limited partners, Frazier’s portfolio companies have snagged more than 60 FDA drug approvals and 34 M&A transactions since 2010. About 43% of Frazier’s venture dollars have historically gone toward creating companies, and the firm likes to take more than 40% ownership in those startups. Meanwhile, about 31% of its venture dollars have gone toward Series A startups and 17% toward Series B-stage companies. Frazier also likes to back entrepreneurs it knows. More than 60% of its private deals involve “repeat FLS teams,” according to the investor presentation. The investment outlook for public biotechs has been relatively dismal in the months since the cautiously optimistic vibe at the JP Morgan Healthcare Conference in January, but the private side of the sector has had a “steady recovery,” according to Raymond James bankers on Monday. The Series A rounds have been mixed; more than $2.1 billion raised so far this year versus $1.4 billion over a similar time frame last year, though the number of rounds is flat. But startups looking for a Series B or later round are in a “hit or miss” dynamic, the bankers added. “While capital raised is up substantially, the number of companies getting financed is flattish,” they wrote. The “theme of ‘less companies funded more comprehensively’ continues to thrive.'” Frazier also invests in public companies. The firm added more than $630 million to its evergreen public fund in the fall.

SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA) granted Breakthrough Therapy Designation for Carteyva® (relmacabtagene autoleucel injection) as second-line treatment in adults with relapsed or refractory large B-cell lymphoma (r/r LBCL) . Carteyva® is an anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product independently developed by JW Therapeutics. Continue Reading The Breakthrough Therapy Designation was supported by the results from the clinical study aimed to assess the efficacy and safety of Carteyva® in Chinese adults with r/r LBCL who were not intended for autologous stem cell transplantation after failure of first-line therapy. This is the first clinical result obtained in Chinese patients. Large B-cell lymphoma is a highly aggressive non-Hodgkin's lymphoma and is the most common subtype of lymphoma in adults. LBCL is a potentially curable disease, but 30-40% of patients still experience refractory or relapse1. Patients who fail first-line treatment have a poor outcome, and although conventional treatment options such as high-dose chemotherapy followed by autologous haematopoietic stem cell transplantation (HDCT/ASCT) are the standard of care, approximately more than half of the patients are not suitable for ASCT due to a variety of reasons such as advanced age, comorbidities, and so on, and there is no standard of care with a very poor outcome2. There are still urgent unmet medical needs to develop additional active therapeutic approaches for the treatment of r/r LBCL. About Relmacabtagene Autoleucel Injection Relmacabtagene autoleucel injection (abbreviated as relma-cel, trade name for oncology indications: Carteyva®) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company). Being the first product of JW Therapeutics, Carteyva® has been approved by NMPA for three indications, including the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy, the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL), and the treatment of adult patients with relapsed or refractory mantle cell lymphoma (r/r MCL) after two or more lines of systemic therapy including bruton tyrosine kinase inhibitors (BTKi), making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, priority review and breakthrough therapy designations. About JWCAR029-216 Study (NCT06093841) This is a phase II, open-label, single-arm, multicenter study which aims to assess the efficacy and safety of Carteyva® in Chinese adults with r/r LBCL who were not intended for autologous stem cell transplantation after failure of first-line therapy. This is the first clinical study to evaluate such novel therapy in Chinese LBCL patients. The study will be conformance with the Chinese clinical practices and will truly reveal the efficacy and safety data in Chinese patients. The study is currently ongoing. Preliminary clinical data found Carteyva® providing outstanding efficacy and good safety profile for r/r LBCL patients, with a best overall response rate of 84%. About JW Therapeutics JW Therapeutics (HKEx:2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China's cell immunotherapy industry. For more information, please visit . Forward-Looking Statements The forward-looking statements are based on the management's expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEx) reports filed by the Company. Unless otherwise noted, the Company is providing this information as of the date it publicized, and expressly disclaims any duty to update information contained in the issues and relevant information, or provide any explanation. For detailed information, please visit the company website: . SOURCE JW Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED